

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
09 November 2017 (09.11.2017)



(10) International Publication Number  
**WO 2017/192458 A1**

(51) International Patent Classification:

A61K 38/22 (2006.01) A61K 9/28 (2006.01)  
A61K 9/00 (2006.01) A61K 47/38 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2017/030435

(22) International Filing Date:

01 May 2017 (01.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/331,148	03 May 2016 (03.05.2016)	US
62/344,271	01 June 2016 (01.06.2016)	US
15/583,695	01 May 2017 (01.05.2017)	US

(71) Applicant: SPECTRIX THERAPEUTICS, LLC  
[US/US]; 2535 E. Southlake Blvd., Suite 200, Southlake,  
TX 76092 (US).

(72) Inventor: TENGLER, Mark; 2535 E. Southlake Blvd.,  
Suite 200, Southlake, TX 76092 (US).

(74) Agent: CHALKER, Daniel, J. et al.; Daniel J. Chalker,  
14951 North Dallas Parkway, Suite 400, Dallas, TX 75254  
(US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS OF PROVIDING THYROID HORMONE OR ANALOGS THEREOF

(57) Abstract: The present invention includes a pharmaceutical composition, and methods of making and using, a pharmaceutical composition comprising one or more thyroid hormone(s) or analogs thereof, wherein a first portion of thyroid hormone(s) is formulated for immediate release and a second portion of thyroid hormone(s) is formulated of modified release, e.g., by forming a drug-resin particle with an ion exchange resin.



WO 2017/192458 A1

## COMPOSITIONS AND METHODS OF PROVIDING THYROID HORMONE OR ANALOGS THEREOF

### TECHNICAL FIELD OF THE INVENTION

5 The present invention relates in general to the field of compositions and methods for the delivery of thyroid hormones or analogs thereof, and more particularly, to novel formulations for the delivery of thyroid hormones.

### BACKGROUND OF THE INVENTION

Without limiting the scope of the invention, its background is described in connection with  
10 treatments for hypothyroidism.

United States Patent No. 9,220,788, issued to Davis, et al., is entitled “Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof.” Briefly, the invention is said to include methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle  
15 form of thyroid hormone agonist, partial agonist or an antagonist thereof, and to promote or inhibit angiogenesis in the subject.

United States Patent No. 7,723,390, issued to Garavani, is entitled, “Pharmaceutical formulations for thyroid hormones”. Briefly, the invention is said to provide for pharmaceutical formulations based on thyroid hormones enabling a safe and stable oral  
20 administration in the framework of the strict therapeutic index prescribed in case of thyroid disorders.

United States Patent Publication No. 20070099841, filed by Moncrief, et al., is entitled “Prodrugs of T3 and T4 with enhanced bioavailability”. These applicants are said to teach compositions of amino acid and peptide conjugates comprising T3 and/or T4. The T3 or T4 is  
25 covalently attached to at least one amino acid via the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain. Also discussed are methods for protecting and administering active agents and methods for treating thyroid disorders.

### SUMMARY OF THE INVENTION

In one embodiment the present invention includes a pharmaceutical composition comprising  
30 one or more thyroid hormones or analogs thereof, wherein the first portion of thyroid hormone

is formulated for immediate release and the second portion of thyroid hormone is formulated of modified release. In one aspect, at least one of the first or second portions of the thyroid hormone(s) are bound to an ion resin. In another aspect, the one or more thyroid hormones are selected from T4, T3, T4 or T3 N-Methyl, T4 or T3 N-Ethyl, T4 or T3 N-Triphenyl, T4 or T3 N-Propyl, T4 or T3 N-Isopropyl, T4 or T3-N-Tertiary butyl, GC-1, DIPTA, Tetrac and Triac. In another aspect, the one or more thyroid hormones are provided in an amount effective to treat hypothyroidism. In another aspect, the composition further comprises one or more pharmaceutically acceptable carriers. In another aspect, the composition further comprises one or more additional biologically active substances. In another aspect, the composition is adapted for the treatment of hypothyroidism. In another aspect, at least one of the thyroid hormones is T4 or T3, and ion exchange resin prevents polymorphism in the crystalline structure of the bound hormone. In another aspect, the binding of thyroid hormone to resin provides a geometric dilution to aid in the ease of manufacturing and increase consistency in dosing. In another aspect, the modified release thyroid hormone is T3. In another aspect, the composition is a liquid suspension, chewable composition, orally disintegrating tablet, sublingual, or a swallowed tablet composition. In another aspect, the one or more thyroid hormones are T4 and T3, and are provided a ratio of T4:T3 is from 1:1 to 20:1. In another aspect, the composition is modified release orally disintegrating tablet. In another aspect, the ion-exchange resin particles are acidic cation exchange resins. In another aspect, the ion-exchange resin particles are basic anion exchange resin. In another aspect, the composition is coated and the coating of the one or more modified release drug resin particles comprises a triggered-release coating that is triggered by a pH change. In another aspect, the composition is coated and the coating is selected from at least one of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/ acrylic acid ethyl esters, or mixtures thereof. In another aspect, the modified release coating is a non-pH dependent controlled release coating. In another aspect, the amount of the one or more thyroid hormones is from 0.013 to 0.30 mg equivalent of levothyroxine sodium per dose. In another aspect, greater than 40%, 50%, 60%, 70%, or 80% of the first thyroid hormone is released within the first 45 minutes after the product is introduced into an in vitro dissolution assay, wherein the conditions of the dissolution assay are an initial dissolution medium of 0.1 N HCL, and after 2 hours, the medium is adjusted to a pH of about 6.8; and the dissolution assay is performed using a USP Apparatus 2. In another aspect, the composition is as set forth in Table 1, 2, or 3.

Another embodiment of the present invention is a pharmaceutical composition comprising thyroid hormone(s) complexed with ion-exchange resin particles to form drug resin particles, wherein the composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated for modified release, wherein the composition has an in vivo fasted serum profile with a first and second peak wherein the first peak occurs before 3 hours after ingestion of the composition and the second peak occurs after 3 hours after ingestion.

Yet another embodiment of the present invention includes a method of making a pharmaceutical composition comprising: attaching thyroid hormone(s) or analogs thereof to ion-exchange resin particles to form drug-resin particles, wherein at least 30 % or more by weight of the first portion of thyroid hormone(s) is formulated for immediate release; and a second portion of thyroid hormone(s) is formulated for modified release. In another aspect, the first and second thyroid hormones are selected from at least one of T4, T3, T4 or T3 N-Methyl, T4 or T3 N-Ethyl, T4 or T3 N-Triphenyl, T4 or T3 N-Propyl, T4 or T3 N-Isopropyl, T4 or T3-N-Tertiary butyl, GC-1, DIPTA, Tetrac and Triac. In another aspect, the one or more thyroid hormones are provided in an amount effective to treat hypothyroidism. In another aspect, the composition further comprises one or more pharmaceutically acceptable carriers. In another aspect, the composition further comprises one or more biologically active substances. In another aspect, the composition is adapted for the treatment of hypothyroidism. In another aspect, the one or more thyroid hormones are T4 and T3, and ion exchange resin prevents polymorphism in the crystalline structure. In another aspect, the modified release thyroid hormone is T3. In another aspect, the composition is a liquid suspension, chewable composition, orally disintegrating tablet, sublingual, or swallowed tablet composition. In another aspect, the one or more thyroid hormones are T4 and T3, and are provided a ratio of T4:T3 is from 1:1 to 20:1. In another aspect, the composition is a modified release orally disintegrating tablet. In another aspect, the ion-exchange resin particles are acidic cation exchange resins. In another aspect, the ion-exchange resin particles are basic anion exchange resin. In another aspect, the coating of the one or more extended release drug resin particles comprises a triggered-release coating that is triggered by a pH change. In another aspect, the coating is selected from at least one of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/ acrylic acid ethyl esters, or mixtures thereof. In another

aspect, the modified release coating is a non-pH dependent controlled release coating. In another aspect, the amount of the one or more thyroid hormone(s) is a 0.013 to 0.30 mg equivalent of levothyroxine sodium per dose. In another aspect, greater than 40%, 50%, 60%, 70%, or 80% of the first thyroid hormone is released within the first 45 minutes after the product is introduced into an in vitro dissolution assay, wherein the conditions of the dissolution assay are an initial dissolution medium of 0.1 N HCL, and after 2 hours, the medium is adjusted to a pH of about 6.8; and the dissolution assay is performed using a USP Apparatus 2. In another aspect, the second portion of thyroid hormone provided for modified release comprises greater than 10% by weight. In another aspect, the composition is as set forth in Table 1, 2, or 3.

Yet another embodiment of the present invention includes a method of evaluating a formulation believed to be useful in treating hypothyroidism, the method comprising: (a) measuring the blood levels of one or more thyroid hormones from a first set of subjects suspected of having hypothyroidism; (b) administering the formulation to a first subset of the patients, and a placebo to a second subset of the patients; (c) repeating step (a) after the administration of the formulation or the placebo; and (d) determining if the formulation reduces the number of hypothyroidism that is statistically significant as compared to any reduction occurring in the second subset of patients, wherein a statistically significant reduction indicates that the formulation is useful in treating hypothyroidism.

Yet another embodiment of the present invention includes a pharmaceutical composition comprising at least two thyroid hormones or analogs thereof, wherein a first thyroid hormone or analogs thereof is formulated for immediate release and wherein a second thyroid hormone or analogs thereof is bound to ion resin particles. In one aspect, the drug-resin particles may be uncoated or coated with an immediate release coating. In one aspect, at least 80% of the drug is released within one hour.

Yet another embodiment of the present invention includes a method of making a pharmaceutical composition comprising attaching thyroid hormone(s) or analogs thereof to ion-exchange resin particles to form drug-resin particles, wherein there is at least 30% or more weight gain in the drug-resin particles. In one aspect, the drug-resin particles may be uncoated or coated with an immediate release coating. In one aspect, at least 80 of the drug is released within one hour.

## DETAILED DESCRIPTION OF THE INVENTION

While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific  
5 embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.

To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to  
10 refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.

As used herein, the term “pharmaceutically effective amount” refers to that amount of an agent effective to produce the intended effect of reducing, and/or preventing hypothyroidism.  
15 Hypothyroidism may be caused by decreased production of thyroid hormones. Such factors include loss of thyroid tissue due to disease or surgery.

Pharmaceutical composition refers to a composition suitable for pharmaceutical use in an animal or animal cell line. The animal may be a mammal, such as a human. A pharmaceutical composition of the invention includes a pharmaceutically effective amount of one or more  
20 thyroid hormones or analogs thereof, and optionally a pharmaceutically acceptable resin.

As used herein, the term “flavorant” is intended to mean a compound used to impart a pleasant flavor and often odor to a pharmaceutical preparation. In addition to the natural flavorants, many synthetic flavorants are also used. Such compounds include, by way of example and without limitation, anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and  
25 vanillin and the like.

As used herein, the term “sweetening agent” is intended to mean a compound used to impart sweetness to a preparation. Such compounds include, by way of example and without limitation, aspartame, dextrose, glycerin, mannitol, saccharin sodium, sorbitol and sucrose and the like.

30 As used herein, the term “tablet antiadherents” is intended to mean agents which prevent the sticking of table formulation ingredients to punches and dies in a tableting machine during

production. Such compounds include, by way of example and without limitation, magnesium stearate, talc, and the like.

As used herein, the term “tablet binders” is intended to mean substances used to cause adhesion of powder particles in table granulations. Such compounds include, by way of example and without limitation, acacia, alginic acid, carboxymethyl cellulose, sodium, compressible sugar  
5 ethylcellulose, gelatin, liquid glucose, methylcellulose, povidone and pregelatinized starch and the like.

As used herein, the term “tablet and capsule diluent” is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the  
10 preparation of tablets and capsules. Such compounds include, by way of example and without limitation, dibasic calcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, and starch and the like.

As used herein, the term “tablet direct compression excipient” is intended to mean a compound used in direct compression tablet formulations. Such compounds include, by way of example  
15 and without limitation, dibasic calcium phosphate and the like.

As used herein, the term “tablet disintegrant” is intended to mean a compound used in solid dosage forms to promote the disruption of the solid mass into smaller particles that are more readily dispersed or dissolved. Such compounds include, by way of example and without  
20 limitation, alginic acid, carboxymethylcellulose, calcium, microcrystalline cellulose, polacrillin potassium, sodium alginate, sodium starch glycolate, and starch and the like.

As used herein, the term “tablet glidant” is intended to mean agents used in tablet and capsule formulations to reduce friction during tablet compression. Such compounds include, by way of  
example and without limitation, colloidal silica, cornstarch, talc, and the like.

As used herein, the term “tablet lubricant” is intended to mean substances used in tablet  
25 formulations to reduce friction during tablet compression. Such compounds include, by way of example and without limitation, calcium stearate, magnesium stearate, mineral oil, stearic acid, zinc stearate, and the like.

As used herein, the term “tablet/capsule opaquant” is intended to mean a compound used to render a capsule or a tablet coating opaque. An opaquant may be used alone or in combination  
30 with a colorant. Such compounds include, by way of example and without limitation, titanium dioxide and the like.

As used herein, the term “tablet polishing agent” is intended to mean a compound used to impart an attractive sheen to coated tablets. Such compounds include, by way of example and without limitation, carnauba wax, white wax, and the like.

5 It should be understood, that compounds used in the art of pharmaceutical formulation generally serve a variety of functions or purposes. Thus, if a compound named herein is mentioned only once or is used to define more than one term herein, its purpose or function should not be construed as being limited solely to that (those) named purpose(s) or function(s).

10 For oral therapeutic administration, the particles containing the active compound(s) may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least the minimal therapeutic amount per dose. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 0.0)1% to about 80% of the weight of the unit. The amount of particles containing the active compound(s) in such therapeutically useful compositions is such that a suitable dosage  
15 will be obtained.

Techniques and compositions for making useful dosage forms using the present invention are described in one or more of the following references: Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingstone,  
20 New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 2007; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remington’s Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference, and the like,  
25 relevant portions incorporated herein by reference.

For example, the one or more thyroid hormones may be included in a tablet. Tablets may contain, e.g., suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents and/or melting agents. For example, oral administration may be in a dosage unit form of a tablet, gelcap, caplet or capsule, the active drug component being  
30 combined with an non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, mixtures thereof, and the like. Suitable binders for use with



the present invention include: starch, gelatin, natural sugars (e.g., glucose or beta-lactose), corn sweeteners, natural and synthetic gums (e.g., acacia, tragacanth or sodium alginate), carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants for use with the invention may include: sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, mixtures thereof, and the like. Disintegrators may include: starch, methyl cellulose, agar, bentonite, xanthan gum, mixtures thereof, and the like.

The thyroid hormone(s) or analogs thereof may also be coupled to one or more soluble, biodegradable, bioacceptable polymers as drug carriers or as a prodrug. Such polymers may include: polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylasparta-midephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues, mixtures thereof, and the like. Furthermore, the thyroid hormone(s) or analogs thereof may be coupled one or more biodegradable polymers to achieve controlled release of the thyroid hormone(s) or analogs thereof, biodegradable polymers for use with the present invention include: polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels, mixtures thereof, and the like.

In one embodiment, gelatin capsules (gelcaps) may include the thyroid hormone(s) or analogs thereof and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Like diluents may be used to make compressed tablets. Both tablets and capsules may be manufactured as immediate-release, mixed-release or modified-release formulations to provide for a range of release of medication over a period of minutes to hours. Compressed tablets may be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere. An enteric coating may be used to provide selective disintegration in, e.g., the gastrointestinal tract. Furthermore, these properties can be imparted directly on the particles themselves to achieve the same effect.

For oral administration in a liquid dosage form, the oral drug components may be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives,

emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents, mixtures thereof, and the like.

Liquid dosage forms for oral administration may also include coloring and flavoring agents that increase patient acceptance and therefore compliance with a dosing regimen. In general, water, 5 a suitable oil, saline, aqueous dextrose (e.g., glucose, lactose and related sugar solutions) and glycols (e.g., propylene glycol or polyethylene glycols) may be used as suitable carriers for parenteral solutions. Solutions for parenteral administration include generally, a water-soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffering salts. Anti-oxidizing agents such as sodium bisulfite, sodium sulfite and/or ascorbic acid, either alone or in 10 combination, are suitable stabilizing agents. Citric acid and its salts and sodium EDTA may also be included to increase stability. In addition, parenteral solutions may include pharmaceutically acceptable preservatives, e.g., benzalkonium chloride, methyl- or propyl-paraben, and/or chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field, 15 relevant portions incorporated herein by reference.

Capsules. Capsules may be prepared by filling standard two-piece hard gelatin capsules each with 10 to 500 milligrams of particles containing active ingredient.

Soft Gelatin Capsules. Active particles are suspended in a digestible oil such as soybean oil, cottonseed oil or olive oil. The active particles are prepared and injected by using a positive 20 displacement pump into gelatin to form soft gelatin capsules containing, e.g., 10-500 micrograms of the active thyroid hormone. The capsules are washed and dried.

Tablets. A large number of tablets are prepared by conventional procedures so that the dosage unit was 10-500 micrograms of active thyroid hormone, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 50-275 milligrams of microcrystalline cellulose, 25 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

To provide an effervescent tablet appropriate amounts of, e.g., monosodium citrate and sodium bicarbonate, are blended together and then roller compacted, in the absence of water, to form flakes that are then crushed to give granulates. The granulates are then combined with the 30 thyroid hormone(s) particles or analogs thereof, drug and/or salt thereof, conventional beading or filling agents and, optionally, sweeteners, flavors and lubricants.

Injectable solution. A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of thyroid hormone(s) or analogs thereof in deionized water and mixed with, e.g., up to 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized using, e.g., ultrafiltration.

- 5 Suspension. An aqueous suspension is prepared for oral administration so that each 5 ml contain 10-500 micrograms of finely divided thyroid hormone(s) or analogs thereof, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 ml of vanillin or suitable flavorant.

For mini-tablets, the active thyroid hormone particles are compressed into a tablet with a  
10 hardness in the range 0.5 to 12 Kp. The hardness of the final tablets is influenced by the linear roller compaction strength used in preparing the granulates, which are influenced by the particle size of, e.g., the monosodium hydrogen carbonate and sodium hydrogen carbonate. For smaller particle sizes, a linear roller compaction strength of about 15 to 20 KN/cm may be used.

The present invention also includes pharmaceutical kits useful, for example, for the treatment of  
15 hypothyroidism, which comprise one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of the one or more thyroid hormones. Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to  
20 those skilled in the art. Printed instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit. It should be understood that although the specified materials and conditions are important in practicing the invention, unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the  
25 invention from being realized.

In one example, the present invention includes a pharmaceutical composition comprising one or more thyroid hormones or analogs thereof, wherein the first thyroid hormone is formulated for immediate release and the second thyroid hormone is formulated of modified release. For example, the one or more of the thyroid hormones are bound to an ion resin. Non-limiting  
30 examples of the one or more thyroid hormones for use with the present invention can be selected from T4, T3, T4 or T3 N-Methyl, T4 or T3 N-Ethyl, T4 or T3 N-Triphenyl, T4 or T3

N-Propyl, T4 or T3 N-Isopropyl, T4 or T3-N-Tertiary butyl, GC-1, DIPTA, Tetrac and Triac. The two or more thyroid hormones are provided in an amount effective to treat hypothyroidism.

In addition to the two or more thyroid hormones, the composition of the present invention may further comprise one or more biologically active substances that help potentiate the activity of the thyroid hormone(s) or analogs thereof. Generally, the composition will be adapted for the treatment of hypothyroidism by providing the most common dosage amounts for the equivalent hormone(s).

In one specific embodiment, the two or more thyroid hormones are T4 and/or T3 attached to an ion exchange resin that prevents polymorphism in the crystalline structure. In another example, binding the thyroid hormone to resin provides a geometric dilution to aid in the ease of manufacturing and increase consistency in dosing. Often, the modified release thyroid hormone is T3. The composition of the present invention can be formulated as a liquid suspension, chewable composition, orally disintegrating tablet, or a swallowed tablet composition.

In another specific example, the two or more thyroid hormones are T4 and T3, and are provided a ratio of T4:T3 is from 1:1 to 20:1. These hormones can be provided as a modified release orally disintegrating tablet. For example, the T4, T3, and/or analogs thereof, can be attached to ion-exchange resin particles are acidic cation exchange resins. For example, the ion-exchange resin particles can be basic anion exchange resin. The resin may be further coated, e.g., coating of the one or more modified release drug resin particles comprises a triggered-release coating that is triggered by a pH change. Certain non-limiting examples of coatings for use with the present invention include, e.g., cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/ acrylic acid ethyl esters, or mixtures thereof. The modified release coating can also be a non-pH dependent controlled release coating.

The dosages of the present invention can vary to meet the needs of an individual user, or can be produced in large batches having specific amounts of the one or more thyroid hormones or equivalents thereof based on the most commonly used amounts. For example, the amount of the one or more thyroid hormones can be from 0.013 to 0.30 mg equivalent of levothyroxine sodium per dose.

The ionic exchange resin and coating can be selected such that greater than 40% of the first thyroid hormone is released within the first 45 minutes after the product is introduced into an in

vitro dissolution assay, wherein the conditions of the dissolution assay are an initial dissolution medium of 0.1 N HCL, and after 2 hours, the medium is adjusted to a pH of about 6.8; and the dissolution assay is performed using a USP Apparatus 2.

Another example of the present invention includes a pharmaceutical composition comprising  
5 thyroid hormone complexed with ion-exchange resin particles to form drug resin particles,  
wherein the composition comprises a first plurality of immediate release drug-resin particles  
and a second plurality of drug-resin particles that are coated for modified release coating,  
wherein the composition has an *in vivo* fasted serum profile with a first and second peak  
wherein the first peak occurs before 3 hours after ingestion of the composition and the second  
10 peak occurs after 3 hours after ingestion.

Another example of the present invention includes a method of making a pharmaceutical  
composition comprising: attaching one or more thyroid hormones or analog thereof with ion-  
exchange resin particles to form drug-resin particles, wherein at least 30 % by weight of the  
first thyroid hormone or more is formulated for immediate release; and a second thyroid  
15 hormone is formulated for modified release.

Another example of the present invention includes a method of evaluating a formulation  
believed to be useful in treating hypothyroidism, the method comprising: a) measuring the  
blood levels of one or more thyroid hormone(s) from a first set of subjects suspected of having  
hypothyroidism; b) administering the formulation to a first subset of the patients, and a placebo  
20 to a second subset of the patients; c) repeating step a) after the administration of the formulation  
or the placebo; and d) determining if the formulation reduces the number of hypothyroidism  
that is statistically significant as compared to any reduction occurring in the second subset of  
patients, wherein a statistically significant reduction indicates that the formulation is useful in  
treating hypothyroidism.

25

Table 1 – Orally Disintegrating Tablet (ODT)

Example Formulation #1 ODT				
Ingredient	Function	Amount per dose (mg)		
		low	high	
Levothyroxine Sodium	Active T4	0.01300	0.500	
Liothyronine Sodium	Active T3	0.00065	0.500	
Duolite AP143	Exchange Resin	0.00065	33.333	
Methacrylic Acid	DR polymer	0.00163	83.333	Can be used together or separately
Ethylcellulose	XR polymer	0.00007	55.556	
Mannitol		40.0	400.0	
Crospovidone		6.0	60.0	
Microcrystalline Cellulose		4.0	40.0	
Fructose		6.0	200.0	
Flavoring		2.0	10.0	
Colloidal Silicon Dioxide		2.0	20.0	
Triethyl Citrate		2.0	8.0	
Sucralose		2.0	8.0	
Lake Blend Coloring		0.4	2.0	
Magnesium Stearate		0.4	2.0	
Polyethylene Glycol		0.2	1.0	

Table 2 - Tablet

Example Formulation #2 Tablet				
Ingredient	Function	Amount per dose (mg)		
		low	high	
Levothyroxine Sodium	Active T4	0.01300	0.500	
Liothyronine Sodium	Active T3	0.00065	0.500	
Duolite AP143	Exchange Resin	0.00065	33.333	

Methacrylic Acid	DR polymer	0.00163	83.333	Can be used together or separately
Ethylcellulose	XR polymer	0.00007	55.556	
Dibasic Calcium Phosphate		30.0	300.0	
Glyceryl Behebate		10.0	100.0	
Stearyl Alcohol		20.0	200.0	
Micro Crystalline Cellulose		30.0	300.0	
Magnesium Stearate		0.4	2.0	
Polyethylene Glycol		0.2	1.0	

Table 3 Sublingual tablet

Example Formulation #3 Sublingual tablet				
Ingredient	Function	Amount per dose (mg)		
		low	high	
Levothyroxine Sodium	Active T4	0.01300	0.500	
Liothyronine Sodium	Active T3	0.00065	0.500	
Duolite AP143	Exchange Resin	0.00065	33.333	
Methacrylic Acid	DR polymer	0.00163	83.333	Can be used together or separately
Ethylcellulose	XR polymer	0.00007	55.556	
Oleic Acid		0.3	3.0	
Polyethylene Glycol		4.0	20.0	
Silica		4.0	15.0	
Mannitol		20.0	50.0	
Sodium starch glycolate		1.0	3.0	
Sodium stearyl fumarate		0.2	1.5	

Table 4

Example Formulation #4 ODT		Amount per dose (mg)	
Ingredient	Function	low	high
Levothyroxine Sodium	Active T4	0.01300	0.500
Liothyronine Sodium	Active T3	0.00065	0.500
Duolite AP143	Exchange Resin	0.00065	33.333
Mannitol		40.0	400.0
Crosspovidone		6.0	60.0
Microcrystalline Cellulose		4.0	40.0
Fructose		6.0	200.0
Flavoring		2.0	10.0
Colloidal Silicon Dioxide		2.0	20.0
Sucralose		2.0	8.0
Lake Blend Coloring		0.4	2.0
Magnesium Stearate		0.4	2.0
Polyethylene Glycol		0.2	1.0

Table 5

Example Formulation #5 Tablet		Amount per dose (mg)	
Ingredient	Function	low	high
Levothyroxine Sodium	Active T4	0.01300	0.500
Liothyronine Sodium	Active T3	0.00065	0.500
Duolite AP143	Exchange Resin	0.00065	33.333
Dibasic Calcium Phosphate		30.0	300.0



Stearyl Alcohol	20.0	200.0
Microcrystalline Cellulose	30.0	300.0
Magnesium Stearate	0.4	2.0
Polyethylene Glycol	0.2	1.0

Table 6

Example Formulation #6 Sublingual tablet				
Ingredient	Function	Amount per dose (mg)		
		low	high	
Levothyroxine Sodium	Active T4	0.01300	0.500	
Liothyronine Sodium	Active T3	0.00065	0.500	
Duolite AP143	Exchange Resin	0.00065	33.333	
Oleic Acid		0.3	3.0	
Polyethylene Glycol		4.0	20.0	
Silica		4.0	15.0	
Manitol		20.0	50.0	
Sodium starch glycolate		1.0	3.0	
Sodium stearyl fumarate		0.2	1.5	

It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.

It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims.

All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated  
5 by reference.

The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the  
10 alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

As used in this specification and claim(s), the words “comprising” (and any form of  
15 comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. In embodiments of any of the compositions and methods provided herein, “comprising” may be  
20 replaced with “consisting essentially of” or “consisting of”. As used herein, the phrase “consisting essentially of” requires the specified integer(s) or steps as well as those that do not materially affect the character or function of the claimed invention. As used herein, the term “consisting” is used to indicate the presence of the recited integer (e.g., a feature, an element, a characteristic, a property, a method/process step or a limitation) or group of integers (e.g.,  
25 feature(s), element(s), characteristic(s), propertie(s), method/process steps or limitation(s)) only.

The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof” is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a  
30 particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled

artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

As used herein, words of approximation such as, without limitation, “about”, “substantial” or “substantially” refers to a condition that when so modified is understood to not necessarily be absolute or perfect but would be considered close enough to those of ordinary skill in the art to warrant designating the condition as being present. The extent to which the description may vary will depend on how great a change can be instituted and still have one of ordinary skilled in the art recognize the modified feature as still having the required characteristics and capabilities of the unmodified feature. In general, but subject to the preceding discussion, a numerical value herein that is modified by a word of approximation such as “about” may vary from the stated value by at least  $\pm 1, 2, 3, 4, 5, 6, 7, 10, 12$  or 15%.

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

What is claimed is:

1. A pharmaceutical composition comprising one or more thyroid hormones or analogs thereof, wherein a first portion of thyroid hormone is formulated for immediate release and a second portion of thyroid hormone is formulated of modified release and the one or more  
5 thyroid hormones are provided in an amount effective to treat hypothyroidism.
2. The composition of claim 1, wherein at least one of the first or second portions of the thyroid hormone(s) are bound to an ion resin, the one or more thyroid hormones are selected from at least one of T4, T3, T4 or T3 N-Methyl, T4 or T3 N-Ethyl, T4 or T3 N-Triphenyl, T4  
10 or T3 N-Propyl, T4 or T3 N-Isopropyl, T4 or T3-N-Tertiary butyl, GC-1, DIPTA, Tetrac, or Triac, and optionally the modified release thyroid hormone is T3.
3. The composition of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable carriers, one or more additional biologically active substances, and wherein the composition is adapted for the treatment of hypothyroidism.
4. The composition of claim 1, wherein at least one of the thyroid hormones is T4 or T3,  
15 and the ion exchange resin prevents polymorphism in the crystalline structure of the bound hormone.
5. The composition of claim 1, wherein the binding of thyroid hormone to resin provides a geometric dilution to aid in the ease of manufacturing and increase consistency in dosing.
6. The composition of claim 1, wherein the composition is a liquid suspension, chewable  
20 composition, orally disintegrating tablet, sublingual, a modified release orally disintegrating tablet, or a swallowed tablet composition.
7. The composition of claim 1, wherein the one or more thyroid hormones are T4 and T3, and are provided a ratio of T4:T3 is from 1:1 to 20:1.
8. The composition of claim 1, wherein the ion-exchange resin particles are an acidic  
25 cation exchange resin, a basic anion exchange resin, and they are optionally coated with a triggered-release coating that is triggered by a pH change or a non-pH dependent controlled release coating.
9. The composition of claim 1, wherein the composition is coated and the coating is selected from at least one of cellulose acetate phthalate, cellulose acetate trimellitate,  
30 hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate,

carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/ acrylic acid ethyl esters, or mixtures thereof.

10. The composition of claim 1, wherein the amount of the one or more thyroid hormones is from 0.013 to 0.30 mg equivalent of levothyroxine sodium per dose.

5 11. The composition of claim 1, wherein greater than 40%, 50%, 60%, 70%, or 80% of the first thyroid hormone is released within the first 45 minutes after the product is introduced into an in vitro dissolution assay, wherein the conditions of the dissolution assay are an initial dissolution medium of 0.1 N HCl, and after 2 hours, the medium is adjusted to a pH of about 6.8, and the dissolution assay is performed using a USP Apparatus 2.

10 12. The composition of claim 1, wherein the composition consists essentially of at least two thyroid hormones or analogs thereof, wherein a first thyroid hormone or analogs thereof is formulated for immediate release and wherein a second thyroid hormone or analogs thereof is bound to ion resin particles, wherein the drug-resin particles may be uncoated or coated with an immediate release coating, wherein at least 80% of the drug is released within one hour, and  
15 wherein the one or more thyroid hormones are selected from at least one of T4, T3, T4 or T3 N-Methyl, T4 or T3 N-Ethyl, T4 or T3 N-Triphenyl, T4 or T3 N-Propyl, T4 or T3 N-Isopropyl, T4 or T3-N-Tertiary butyl, GC-1, DIPTA, Tetrac, or Triac.

13. A pharmaceutical composition comprising thyroid hormone(s) complexed with ion-exchange resin particles to form drug resin particles, wherein the composition comprises a first  
20 plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated for modified release, wherein the composition has an *in vivo* fasted serum profile with a first and second peak wherein the first peak occurs before 3 hours after ingestion of the composition and the second peak occurs after 3 hours after ingestion.

14. A method of making a pharmaceutical composition comprising:

25 Attaching one or more thyroid hormone(s) or analogs thereof to ion-exchange resin particles to form drug-resin particles, wherein at least 30 % or more by weight of the first portion of thyroid hormone(s) is formulated for immediate release in an amount effective to treat hypothyroidism; and

30 a second portion of thyroid hormone(s) is formulated for modified release and optionally one or more pharmaceutically acceptable carriers.

15. The method of claim 14, wherein the one or more thyroid hormones are selected from T4, T3, T4 or T3 N-Methyl, T4 or T3 N-Ethyl, T4 or T3 N-Triphenyl, T4 or T3 N-Propyl, T4 or T3 N-Isopropyl, T4 or T3-N-Tertiary butyl, GC-1, DIPTA, Tetrac and Triac, and optionally the modified release thyroid hormone is T3.
- 5 16. The method of claim 14, wherein the composition further comprises one or more pharmaceutically acceptable carriers, one or more additional biologically active substances, and wherein the composition is adapted for the treatment of hypothyroidism.
17. The method of claim 14, wherein at least one of the thyroid hormones is T4 or T3, and ion exchange resin prevents polymorphism in the crystalline structure of the bound hormone.
- 10 18. The method of claim 14, further comprising binding of thyroid hormone to resin provides a geometric dilution to aid in the ease of manufacturing and increase consistency in dosing.
19. The method of claim 14, further comprising formulating the composition as a liquid suspension, a chewable composition, an orally disintegrating tablet, a sublingual tablet, a  
15 modified release orally disintegrating tablet, or a swallowed tablet.
20. The method of claim 14, wherein the one or more thyroid hormones are T4 and T3, and are provided a ratio of T4:T3 is from 1:1 to 20:1.
21. The method of claim 14, wherein the resin particles are ion-exchange resin particles selected from at least one of an acidic cation exchange resin or a basic anion exchange resin,  
20 and the resin particles are optionally coated with a triggered-release coating that is triggered by a pH change or a non-pH dependent controlled release coating.
22. The method of claim 14, further comprising coating the composition with a coating selected at least one of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-  
25 copolymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/acrylic acid ethyl esters, or mixtures thereof.
23. The method of claim 14, wherein the amount of the one or more thyroid hormones is from 0.013 to 0.30 mg equivalent of levothyroxine sodium per dose.
24. The method of claim 14, wherein greater than 40%, 50%, 60%, 70%, or 80% of the first  
30 thyroid hormone is released within the first 45 minutes after the product is introduced into an in vitro dissolution assay, wherein the conditions of the dissolution assay are an initial dissolution

medium of 0.1 N HCl, and after 2 hours, the medium is adjusted to a pH of about 6.8, and the dissolution assay is performed using a USP Apparatus 2.

25. The method of claim 14, wherein the second portion of thyroid hormone provided for modified release comprises greater than 10% by weight.

5 26. The method of claim 14, further comprising attaching thyroid hormone(s) or analogs thereof to ion-exchange resin particles to form drug-resin particles, wherein there is at least 30% or more weight gain in the drug-resin particles.

27. A method of evaluating a formulation believed to be useful in treating hypothyroidism, the method comprising:

10 (a) measuring the blood levels of one or more thyroid hormones from a first set of subjects suspected of having hypothyroidism;

(b) administering the formulation to a first subset of the patients, and a placebo to a second subset of the patients, wherein the formulation comprises one or more thyroid hormones or analogs thereof, wherein a first portion of thyroid hormone is formulated for immediate  
15 release and a second portion of thyroid hormone is formulated of modified release and the one or more thyroid hormones are provided in an amount effective to treat hypothyroidism;

(c) repeating step (a) after the administration of the formulation or the placebo; and

(d) determining if the formulation reduces the number of hypothyroidism that is statistically significant as compared to any reduction occurring in the second subset of patients,  
20 wherein a statistically significant reduction indicates that the formulation is useful in treating hypothyroidism.

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 27  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claim 27 contains a method for treatment of the human body by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.



**A. CLASSIFICATION OF SUBJECT MATTER****A61K 38/22(2006.01)i, A61K 9/00(2006.01)i, A61K 9/28(2006.01)i, A61K 47/38(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K 38/22; A61K 9/14; B05D 5/00; A61K 9/20; A61K 31/785; A61K 9/127; A61K 31/198; A61K 31/485; A61K 9/00; A61K 9/28; A61K 47/38

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models  
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) &amp; Keywords: pharmaceutical composition, ion-exchange resin, thyroid hormone, T4, T3, modified release, immediate release, hypothyroidism

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2005-0181050 A1 (HIRSH et al.) 18 August 2005 See abstract; claims 1, 11-15, 22; and paragraphs [0018], [0029], [0069]-[0082], [0115].	1-26
Y	US 2004-0152783 A1 (OLON et al.) 05 August 2004 See claim 1; and paragraphs [0029]-[0038].	1-26
A	US 2012-0064167 A1 (HALL et al.) 15 March 2012 See the whole document.	1-26
A	US 2015-0024059 A1 (TRIS PHARMA, INC.) 22 January 2015 See the whole document.	1-26
A	US 8668926 B1 (MOUSA et al.) 11 March 2014 See the whole document.	1-26

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

28 August 2017 (28.08.2017)

Date of mailing of the international search report

**29 August 2017 (29.08.2017)**

Name and mailing address of the ISA/KR

International Application Division  
Korean Intellectual Property Office  
189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

LEE GYONG CHEOL

Telephone No. +82-42-481-8611



**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2017/030435**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2005-0181050 A1	18/08/2005	CA 2596035 A1	03/08/2006
		EP 1846040 A2	24/10/2007
		US 2005-0255048 A1	17/11/2005
		US 2007-0036843 A1	15/02/2007
		US 2007-0232695 A1	04/10/2007
		WO 2006-081518 A2	03/08/2006
		WO 2006-081518 A3	23/11/2006
		US 2004-0152783 A1	05/08/2004
EP 1565171 A2	24/08/2005		
EP 1565171 A4	30/06/2010		
WO 2004-041208 A2	21/05/2004		
WO 2004-041208 A3	03/02/2005		
US 2012-0064167 A1	15/03/2012	CA 2757337 A1	07/10/2010
		EP 2413898 A1	08/02/2012
		US 9238078 B2	19/01/2016
		WO 2010-115015 A1	07/10/2010
US 2015-0024059 A1	22/01/2015	AU 2007-227569 A1	27/09/2007
		AU 2007-227569 B2	12/09/2013
		CA 2645855 A1	27/09/2007
		CA 2645855 C	03/02/2015
		CN 101400343 A	01/04/2009
		CN 101400343 B	11/01/2012
		CN 102488652 A	13/06/2012
		CN 102488652 B	18/06/2014
		EP 2018160 A2	28/01/2009
		EP 2018160 B1	14/12/2011
		EP 2428205 A1	14/03/2012
		EP 2428205 B1	03/10/2012
		IL 194042 A	03/08/2009
		JP 2009-530298 A	27/08/2009
		JP 5479086 B2	23/04/2014
		KR 10-1495146 B1	24/02/2015
		KR 10-2008-0108520 A	15/12/2008
		RU 2008-140944 A	27/04/2010
		RU 2435569 C2	10/12/2011
		TW 2008-12649 A	16/03/2008
		US 2007-0215511 A1	20/09/2007
		US 2010-0166858 A1	01/07/2010
		US 2012-0015030 A1	19/01/2012
		US 2013-0059007 A1	07/03/2013
		US 2013-0136797 A1	30/05/2013
		US 2014-0030334 A1	30/01/2014
US 2014-0056984 A1	27/02/2014		
US 2014-0127306 A1	08/05/2014		
US 2015-0272893 A1	01/10/2015		
US 2016-0158373 A1	09/06/2016		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2017/030435**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2016-0310438 A1	27/10/2016
		US 2016-0310449 A1	27/10/2016
		US 2016-0310478 A1	27/10/2016
		US 2017-0100487 A1	13/04/2017
		US 8062667 B2	22/11/2011
		US 8202537 B2	19/06/2012
		US 8337890 B2	25/12/2012
		US 8491935 B2	23/07/2013
		US 8597684 B2	03/12/2013
		US 8747902 B2	10/06/2014
		US 8790700 B2	29/07/2014
		US 8883217 B2	11/11/2014
		US 9198864 B2	01/12/2015
		US 9522191 B2	20/12/2016
		US 9549989 B2	24/01/2017
		US 9675703 B2	13/06/2017
		US 9675704 B2	13/06/2017
		WO 2007-109104 A2	27/09/2007
		WO 2007-109104 A3	13/12/2007
US 8668926 B1	11/03/2014	US 2014-199376 A1	17/07/2014
		US 2014-314665 A1	23/10/2014
		US 9579300 B2	28/02/2017